CJC-1295 research guide for Regola. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Unlike everyday supplements stocked in every health store, CJC-1295 moves through a specialist research supply market that Regola residents navigate through international suppliers. What this means for Regola researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those evaluation tools are available to every researcher. Separating properly characterised CJC-1295 from the rest of the market requires three things: an HPLC chromatogram confirming ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. This guide guides Regola researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Regola comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Evaluating CJC-1295 vendors begins with the COA: request the batch-specific certificate before placing an order, not after. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are within acceptable research limits. Strong quality indicators beyond COA quality: multi-year operating history, responsive technical support who understand testing methodology, and shipping with desiccant and appropriate cold protection. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the quantity required for your immediate research and keep the remainder frozen.
Order CJC-1295 — ships to Regola
COA-verified · International tracking · Research grade
CJC-1295 is supplied strictly for research applications and is not approved for human use by the FDA or comparable health authorities — all information here is for educational purposes only. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution kept at 2-8°C refrigerated and finished within 30 days of reconstitution; reconstitute only with sterile bacteriostatic water. Quality CJC-1295 sourcing is inseparable from safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that proper COA verification addresses. Researchers using CJC-1295 alongside other research compounds should review the available literature for documented interactions before beginning combination research.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
